138 related articles for article (PubMed ID: 36102904)
1. Imeglimin in type 2 diabetes.
Huston J; Schaffner H; Langley L; Skrable B; Ashchi A; Berner J; Gore A; Sheikh-Ali M; Sutton D; Goldfaden R
Drugs Today (Barc); 2022 Sep; 58(9):437-449. PubMed ID: 36102904
[TBL] [Abstract][Full Text] [Related]
2. Imeglimin: the New Kid on the Block.
Shrestha SC; Gupta S
Curr Diab Rep; 2024 Jan; 24(1):13-18. PubMed ID: 38051432
[TBL] [Abstract][Full Text] [Related]
3. Molecular Mechanisms by Which Imeglimin Improves Glucose Homeostasis.
Yaribeygi H; Maleki M; Sathyapalan T; Jamialahmadi T; Sahebkar A
J Diabetes Res; 2020; 2020():8768954. PubMed ID: 32215274
[TBL] [Abstract][Full Text] [Related]
4. Imeglimin Hydrochloride: First Approval.
Lamb YN
Drugs; 2021 Sep; 81(14):1683-1690. PubMed ID: 34472031
[TBL] [Abstract][Full Text] [Related]
5. Imeglimin: Current Development and Future Potential in Type 2 Diabetes.
Konkwo C; Perry RJ
Drugs; 2021 Feb; 81(2):185-190. PubMed ID: 33247829
[TBL] [Abstract][Full Text] [Related]
6. Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes.
Pacini G; Mari A; Fouqueray P; Bolze S; Roden M
Diabetes Obes Metab; 2015 Jun; 17(6):541-545. PubMed ID: 25694060
[TBL] [Abstract][Full Text] [Related]
7. A review of phenformin, metformin, and imeglimin.
Yendapally R; Sikazwe D; Kim SS; Ramsinghani S; Fraser-Spears R; Witte AP; La-Viola B
Drug Dev Res; 2020 Jun; 81(4):390-401. PubMed ID: 31916629
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and Biological Properties of Imeglimin Hydrochlo ride, A Novel Antidiabetic Agent: A Systematic Review.
Sultan J; Agarwal N; Sharma S
Curr Diabetes Rev; 2024; 20(5):e171023222286. PubMed ID: 37855361
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
Fouqueray P; Pirags V; Inzucchi SE; Bailey CJ; Schernthaner G; Diamant M; Lebovitz HE
Diabetes Care; 2013 Mar; 36(3):565-8. PubMed ID: 23160726
[TBL] [Abstract][Full Text] [Related]
10. Exploring new mechanisms of Imeglimin in diabetes treatment: Amelioration of mitochondrial dysfunction.
Li Y; Lou N; Liu X; Zhuang X; Chen S
Biomed Pharmacother; 2024 Jun; 175():116755. PubMed ID: 38772155
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52-week, open-label, multicentre phase 3 trial.
Dubourg J; Fouqueray P; Quinslot D; Grouin JM; Kaku K
Diabetes Obes Metab; 2022 Apr; 24(4):609-619. PubMed ID: 34866306
[TBL] [Abstract][Full Text] [Related]
12. Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitus.
Dubourg J; Perrimond-Dauchy S; Felices M; Bolze S; Voiriot P; Fouqueray P
Eur J Clin Pharmacol; 2020 Oct; 76(10):1393-1400. PubMed ID: 32556539
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacological profile and clinical efficacy of imeglimin hydrochloride (TWYMEEG
Nagamine J
Nihon Yakurigaku Zasshi; 2023; 158(2):193-202. PubMed ID: 36858505
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy.
Fouqueray P; Pirags V; Diamant M; Schernthaner G; Lebovitz HE; Inzucchi SE; Bailey CJ
Diabetes Care; 2014 Jul; 37(7):1924-30. PubMed ID: 24722500
[TBL] [Abstract][Full Text] [Related]
15. Preservation effect of imeglimin on pancreatic β-cell mass: Noninvasive evaluation using
Fauzi M; Murakami T; Fujimoto H; Botagarova A; Sakaki K; Kiyobayashi S; Ogura M; Inagaki N
Front Endocrinol (Lausanne); 2022; 13():1010825. PubMed ID: 36246910
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Imeglimin for Type 2 Diabetes in Patients Undergoing Dialysis.
Mima A
In Vivo; 2023; 37(3):1334-1338. PubMed ID: 37103109
[TBL] [Abstract][Full Text] [Related]
17. Different doses of imeglimin for management of type 2 diabetes mellitus: a systematic review, meta-analysis, and meta-regression of randomized clinical trials.
Permana H; Soetedjo NNM; Yanto TA; Tendean M; Hariyanto TI; Suastika K
Expert Rev Endocrinol Metab; 2024; 19(1):89-98. PubMed ID: 38047423
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes.
Hallakou-Bozec S; Vial G; Kergoat M; Fouqueray P; Bolze S; Borel AL; Fontaine E; Moller DE
Diabetes Obes Metab; 2021 Mar; 23(3):664-673. PubMed ID: 33269554
[TBL] [Abstract][Full Text] [Related]
19. Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents.
Perry RJ; Cardone RL; Petersen MC; Zhang D; Fouqueray P; Hallakou-Bozec S; Bolze S; Shulman GI; Petersen KF; Kibbey RG
Am J Physiol Endocrinol Metab; 2016 Aug; 311(2):E461-70. PubMed ID: 27406738
[TBL] [Abstract][Full Text] [Related]
20. Issues surrounding tight glycemic control in people with type 2 diabetes mellitus.
Cerveny JD; Leder RD; Weart CW
Ann Pharmacother; 1998 Sep; 32(9):896-905. PubMed ID: 9762378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
